The coronavirus vaccine developed by Valneva was successful in a late-stage clinical trial, the French company announced on Monday.
Based on a trial with 4,012 participants, Valneva said that its vaccine prevented coronavirus infections at a similar rate to the Oxford/AstraZeneca shot. It also stimulated the creation of protective antibodies at a higher rate than the vaccine with which it was being compared.
The Valneva shot is the only vaccine on clinical trial in Europe based on an inactivated, adjuvanted virus vector — a more traditional form of vaccine than mRNA or adenoviral-vector shots. Similar technology is used in the Chinese vaccines from Sinopharm and Sinovac.
In terms of safety, Valneva said that participants who received its vaccine reported “significantly fewer” adverse side-effects when compared with Oxford/AstraZeneca.
Analysis shows that the shot provoked the creation of a broad spectrum of T-cells, which along with antibodies give protection against the coronavirus, and which are understood to be linked with long-term immunity.
If Valneva is approved it could help further diversify vaccine production and the use of an inactivated virus vector could also benefit the developing world which already has facilities to manufacture the older technology.
The French company has already submitted its vaccine candidate to the U.K.’s medicines regulator for rolling review, and said that final quality controls were taking place before it submitted a final clinical study report. It was preparing to submit a rolling review application with the European Medicines Agency, Valneva added.